IFI16 and breast cancer: Downregulation of interferon-γ inducible protein 16 (IFI16), a direct target of EZH2, decreases stimulator of interferon genes (STING) activation and downstream CXCL10/11 expression in response to trastuzumab treatment in HER2+ breast cancer (BC).